Oncology One

Oncology One is an Australian biotechnology company dedicated to developing innovative small molecule therapeutics for the treatment of cancer. The company utilizes a capital-efficient, virtual R&D model to advance a pipeline of high-potential oncology assets sourced from leading academic and research institutions. Their lead programs focus on targeting the Casein Kinase 1 (CK1) and Ribosomal S6 Kinase (RSK) families, which are implicated in various solid tumors and hematological malignancies. By bridging the gap between early-stage research and clinical application, Oncology One aims to deliver new treatment options for patients with hard-to-treat cancers. The company is headquartered in Melbourne and maintains strong collaborations with Australia's premier cancer research centers. This approach allows the firm to de-risk novel targets and progress them toward clinical proof-of-concept.